Migraine Drugs Market
Migraine Drugs Market - Global Industry Assessment & Forecast
#
Pages:
215
Base Year:
2023
Dec - 2024
Format:
Report Code:
VMR-3915
Segments Covered
By
Treatment Acute, Preventive
-
By
Therapeutic class CGRP Monoclonal Antibodies, CGRP Small Molecule Antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs
-
By
Route of Administration Oral, Injectable, Others
-
By
Age group Pediatric, Adult, Geriatric
-
By
Availability prescription drugs, Over-the-Counter (OTC) drugs
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 6.37 Billion |
 Revenue 2032:
|
USD 21.59 Billion |
 Revenue CAGR
(2024 - 2032): |
11.75% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacfic |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Migraine Drugs Market Segment Analysis
- Migraine Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Acute
- Preventive
- Migraine Drugs Therapeutic class Outlook (Revenue, USD Million, 2018 - 2030)
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Migraine Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Injectable
- Others
- Migraine Drugs Age group Outlook (Revenue, USD Million, 2018 - 2030)
- Pediatric
- Adult
- Geriatric
- Migraine Drugs Availability Outlook (Revenue, USD Million, 2018 - 2030)
- prescription drugs
- Over-the-Counter (OTC) drugs
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Migraine Drugs Market, by Treatment
- Acute
- Preventive
-
North America Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
-
North America Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
-
North America Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
-
North America Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- U.S.
- U.S. Migraine Drugs Market, by Treatment
- Acute
- Preventive
- U.S. Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- U.S. Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- U.S. Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- U.S. Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- U.S. Migraine Drugs Market, by Treatment
- Canada
- Canada Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Canada Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Canada Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Canada Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Canada Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Canada Migraine Drugs Market, by Treatment
-
Mexico
- Mexico Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Mexico Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Mexico Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Mexico Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Mexico Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Mexico Migraine Drugs Market, by Treatment
-
North America Migraine Drugs Market, by Treatment
- Europe
-
Europe Migraine Drugs Market, by Treatment
- Acute
- Preventive
-
Europe Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
-
Europe Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
-
Europe Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
-
Europe Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- U. K.
- U.K. Migraine Drugs Market, by Treatment
- Acute
- Preventive
- U.K. Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- U.K. Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- U.K. Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- U.K. Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- U.K. Migraine Drugs Market, by Treatment
- France
- France Migraine Drugs Market, by Treatment
- Acute
- Preventive
- France Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- France Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- France Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- France Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- France Migraine Drugs Market, by Treatment
-
Germany
- Germany Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Germany Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Germany Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Germany Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Germany Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Germany Migraine Drugs Market, by Treatment
-
Italy
- Italy Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Italy Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Italy Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Italy Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Italy Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Italy Migraine Drugs Market, by Treatment
-
Spain
- Spain Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Spain Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Spain Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Spain Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Spain Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Spain Migraine Drugs Market, by Treatment
-
Rest of Europe
- Rest of Europe Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Rest of Europe Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Rest of Europe Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Rest of Europe Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Rest of Europe Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Rest of Europe Migraine Drugs Market, by Treatment
-
Europe Migraine Drugs Market, by Treatment
- Asia Pacific
-
Asia Pacific Migraine Drugs Market, by Treatment
- Acute
- Preventive
-
Asia Pacific Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
-
Asia Pacific Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
-
Asia Pacific Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
-
Asia Pacific Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- China
- China Migraine Drugs Market, by Treatment
- Acute
- Preventive
- China Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- China Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- China Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- China Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- China Migraine Drugs Market, by Treatment
- Japan
- Japan Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Japan Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Japan Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Japan Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Japan Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Japan Migraine Drugs Market, by Treatment
-
Germany
- Germany Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Germany Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Germany Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Germany Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Germany Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Germany Migraine Drugs Market, by Treatment
-
India
- India Migraine Drugs Market, by Treatment
- Acute
- Preventive
- India Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- India Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- India Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- India Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- India Migraine Drugs Market, by Treatment
-
South Korea
- South Korea Migraine Drugs Market, by Treatment
- Acute
- Preventive
- South Korea Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- South Korea Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- South Korea Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- South Korea Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- South Korea Migraine Drugs Market, by Treatment
-
South East Asia
- South East Asia Migraine Drugs Market, by Treatment
- Acute
- Preventive
- South East Asia Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- South East Asia Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- South East Asia Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- South East Asia Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- South East Asia Migraine Drugs Market, by Treatment
-
Rest of Asia Pacific
- Rest of Asia Pacific Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Rest of Asia Pacific Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Rest of Asia Pacific Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Rest of Asia Pacific Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Rest of Asia Pacific Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Rest of Asia Pacific Migraine Drugs Market, by Treatment
-
Asia Pacific Migraine Drugs Market, by Treatment
- Latin America
-
Latin America Migraine Drugs Market, by Treatment
- Acute
- Preventive
-
Latin America Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
-
Latin America Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
-
Latin America Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
-
Latin America Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Brazil
- Brazil Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Brazil Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Brazil Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Brazil Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Brazil Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Brazil Migraine Drugs Market, by Treatment
- Argentina
- Argentina Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Argentina Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Argentina Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Argentina Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Argentina Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Argentina Migraine Drugs Market, by Treatment
-
Rest of Latin America
- Rest of Latin America Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Rest of Latin America Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Rest of Latin America Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Rest of Latin America Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Rest of Latin America Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Rest of Latin America Migraine Drugs Market, by Treatment
-
Latin America Migraine Drugs Market, by Treatment
- Middle East & Africa
-
Middle East & Africa Migraine Drugs Market, by Treatment
- Acute
- Preventive
-
Middle East & Africa Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
-
Middle East & Africa Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
-
Middle East & Africa Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
-
Middle East & Africa Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- GCC Countries
- GCC Countries Migraine Drugs Market, by Treatment
- Acute
- Preventive
- GCC Countries Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- GCC Countries Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- GCC Countries Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- GCC Countries Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- GCC Countries Migraine Drugs Market, by Treatment
- South Africa
- South Africa Migraine Drugs Market, by Treatment
- Acute
- Preventive
- South Africa Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- South Africa Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- South Africa Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- South Africa Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- South Africa Migraine Drugs Market, by Treatment
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Migraine Drugs Market, by Treatment
- Acute
- Preventive
- Rest of Middle East & Africa Migraine Drugs Market, by Therapeutic class
- CGRP Monoclonal Antibodies
- CGRP Small Molecule Antagonists
- Acetylcholine inhibitors/ neurotoxins
- Triptans
- Ditans
- Ergot alkaloids
- NSAIDs
- Rest of Middle East & Africa Migraine Drugs Market, by Route of Administration
- Oral
- Injectable
- Others
- Rest of Middle East & Africa Migraine Drugs Market, by Age group
- Pediatric
- Adult
- Geriatric
- Rest of Middle East & Africa Migraine Drugs Market, by Availability
- prescription drugs
- Over-the-Counter (OTC) drugs
- Rest of Middle East & Africa Migraine Drugs Market, by Treatment
-
Middle East & Africa Migraine Drugs Market, by Treatment
- North America
FAQ
Frequently Asked Question
What is the global demand for Migraine Drugs in terms of revenue?
-
The global Migraine Drugs valued at USD 6.37 Billion in 2023 and is expected to reach USD 21.59 Billion in 2032 growing at a CAGR of 11.75%.
Which are the prominent players in the market?
-
The prominent players in the market are AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., GSK plc, Eli Lilly and Company, Pfizer Inc., Bausch Health Companies Inc., Gensco Pharma, Impel Pharmaceuticals Inc., Tonix Medicines, Inc., Currax Pharmaceuticals LLC., Lundbeck.
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 11.75% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Migraine Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Migraine Drugs in 2023.
